Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study - ACR Meeting Abstracts
GAIN-2 - GBG 68
About ARANESP® (darbepoetin alfa) | Amgen ESA | HCP
Overview of selected cetuximab q2w dosing studies in which KRAS... | Download Table
Patient disposition. QW = once weekly, Q2W = once every 2 weeks, Q3W =... | Download Scientific Diagram
Patient disposition. QW = once weekly, Q2W = once every 2 weeks, Q3W =... | Download Scientific Diagram
Dupixent II-27 - EPAR
Mean plasma concentration vs time curves for andecaliximab Q2W and QW.... | Download Scientific Diagram
Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial - ACR Meeting Abstracts
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer | British Journal of Cancer
Stephen V Liu, MD on Twitter: "RR 23% overall. With q2w dosing, RR 28%. mDOR 8.7m. In non-squamous, RR 18% (q2w RR 31%, q3w RR 6%). In squamous, RR 43% (all in
Overview of selected cetuximab q2w dosing studies in which KRAS... | Download Table
Overview of selected cetuximab q2w dosing studies in which KRAS... | Download Table
Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study | springermedizin.de
g66721mmi001.jpg
GAIN-2 - GBG 68
Flexible dosing options for mNSCLC | TECENTRIQ® (atezolizumab)
Patient disposition. QW = once weekly, Q2W = once every 2 weeks, Q3W =... | Download Scientific Diagram
Dosing & Administration - IMFINZI® (durvalumab)
Dosing & Administration - IMFINZI® (durvalumab)
Study design. IV intravenous, MTD maximum tolerated dose, Q2W once... | Download Scientific Diagram
Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study | International Journal of Dermatology and Venereology
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial - ScienceDirect
Cancers | Free Full-Text | Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label,
Folie 1
Overview of selected cetuximab q2w dosing studies in which KRAS... | Download Table
